NCT07144657View on ClinicalTrials.gov

Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2030

Conditions
MALT Lymphoma of Stomach
Interventions
DRUG

Esomeprazole, Bismuth tripotassium dicitrate, Tetracycline, and Metronidazole

"1. Frontline antibiotics treatment (two weeks of quadruple HPE regimens followed by 4 weeks of clarithromycin).~2. If no response to frontline antibiotics treatment, second line immune-modulator regimens (CAMC, clarithromycin (CAM) and low-dose cyclophosphamide) will be prescribed"

Trial Locations (1)

100

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER